
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Explore how Samsung Biologics’ DEVELOPICK™ can help mitigate development risk and identify candidates with the best potential for advancement to IND and beyond





